The Claim
In adults with heterozygous familial hypercholesterolemia (HeFH) who are already on statin therapy, the daily administration of 20 mg oral enlicitide for 52 weeks results in a sustained reduction in low-density lipoprotein cholesterol (LDL-C), with a mean percentage change of −55.3% at one year compared to a +8.7% change in the placebo group, yielding a between-group difference of −61.5% (95% CI: −69.4% to −53.7%, p < 0.001), demonstrating durable lipid-lowering effects over 12 months.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with a genetic cholesterol problem who are already on cholesterol meds, taking a pill called enlicitide every day for a year keeps their bad cholesterol way down — cutting it by more than half — while those not taking it see their levels go up.
See the scientific wording
In adults with heterozygous familial hypercholesterolemia (HeFH) on statin therapy, daily 20 mg oral enlicitide for 52 weeks maintains a substantial reduction in LDL-C, with a mean percentage change of −55.3% at one year compared to +8.7% in the placebo group, resulting in a between-group difference of −61.5% (95% CI: −69.4% to −53.7%, p < 0.001), indicating durable lipid-lowering effects over 12 months.
What the research says
1 studyThe study tested the same pill, dose, and patient group as described in the claim, and found it worked just as well as claimed—lowering bad cholesterol significantly over a year.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.